CancerInsilico Medicine discovers new CDK inhibitorsInsilico Medicine Inc. has patented cyclin-dependent kinase (CDK) inhibitors, particularly CDK2/cyclin E1 and/or and CDK4/cyclin D3, reported to be useful for the treatment of cancer.